Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye. The company’s proprietary hydrogel-based delivery platforms are engineered to provide sustained release of therapeutic agents directly to ocular tissues, with the goal of improving patient compliance and outcomes compared to traditional eye drops or injections.
The company’s first commercially approved product, DEXTENZA (dexamethasone ophthalmic insert), is a preservative-free, intracanalicular insert designed to deliver a controlled dose of corticosteroid to treat ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix also markets ReSure Sealant, the first FDA-approved ocular wound sealant for cataract surgery, which helps to protect incisions and reduce the risk of postoperative complications without the need for sutures.
Beyond its approved products, Ocular Therapeutix maintains a robust clinical pipeline targeting unmet needs in retinal and anterior segment diseases. Key investigational programs include OTX-TKI, a sustained-release tyrosine kinase inhibitor for wet age-related macular degeneration; OTX-TIC, a travoprost intracanalicular insert for glaucoma; and OTX-CSI, a corticosteroid insert for chronic non-infectious anterior uveitis. These candidates leverage the company’s hydrogel platform to address patient adherence challenges and provide extended therapeutic coverage with a single administration.
Founded in 2008 and headquartered in Bedford, Massachusetts, Ocular Therapeutix conducts preclinical and clinical activities in the United States while exploring partnership opportunities to expand its global footprint. Under the leadership of President and Chief Executive Officer Antony Mattessich, the company continues to advance its mission of transforming the standard of care in ophthalmology by delivering novel, sustained-release treatments directly to the eye.
AI Generated. May Contain Errors.
